Tuesday 27 Jun 2017 @ 12:10
Competition & Markets Authority
Printable version

CMA applies discretion not to refer IBA/Mallinckrodt merger

The CMA is not referring the merger between IBA and Mallinckrodt’s global nuclear imaging business for an in-depth investigation.

The companies both supply single photon emission computed tomography (SPECT) radiopharmaceuticals in the UK. These are used to diagnose disease in many different tissues and organs including bones, the brain, heart, kidneys, liver, and lungs.

The Competition and Markets Authority (CMA) has found that in one category of SPECT products supplied by the companies the merger will reduce the number of suppliers from 3 to 2 and this could substantially lessen competition. However, the size of the relevant market is below £5 million and the CMA has not found reasons to warrant an in-depth phase 2 investigation. Therefore, the CMA has decided to apply its statutory discretion not to refer this case.

This is the first case in which the CMA has exercised its discretion not to make a reference for this reason since publishing revised guidance on 16 June.

For more information, please see the case page.

 

Channel website: https://www.gov.uk/government/organisations/competition-and-markets-authority

Share this article

Latest News from
Competition & Markets Authority

CMA could approve Synopsys / Ansys merger if competition concerns are resolved

20/12/2024 16:10:00

Synopsys’ purchase of Ansys raises competition concerns in the supply of semiconductor chip design and light simulation products in the UK – but deal could be approved by the CMA if its concerns are resolved.

CMA probes possible bid-rigging in relation to school improvement fund

12/12/2024 12:20:00

The CMA has launched an investigation into suspected bid-rigging in relation to a key government fund for improving the condition of school buildings.

NHS set to benefit from £23 million following CMA pharma probe

11/12/2024 09:20:00

The CMA has secured an offer of £23m from Vifor Pharma to the NHS, as part of a wider package, to address concerns that doctors were given potentially misleading information.

CMA clears Vodafone / Three merger, subject to legally binding commitments

05/12/2024 13:10:00

Proposed commitments would ensure the merger boosts competition in UK telecoms with rollout of 5G connectivity.

High fuel margins continue to inflate pump prices for motorists

28/11/2024 16:20:00

Today’s interim monitoring report sets out the CMA's observations on developments in the road fuel retail market since the previous update in July 2024.

Groceries: Loyalty prices offer genuine savings, says CMA

28/11/2024 11:05:00

The CMA looked at thousands of products to see if loyalty prices offered genuine savings – the evidence says yes.

Keynote speech to the BIICL Tech Antitrust Roundtable 2024

26/11/2024 12:20:00

The keynote speech delivered by Jessica Lennard, Chief Strategy and External Affairs Officer, to the 6th Annual BIICL Technology and Antitrust Roundtable

CMA publishes provisional findings in Mobile Browsers and Cloud Gaming market investigation

25/11/2024 10:25:00

Findings by an independent inquiry group suggest Apple’s policies are holding back innovation in the browsers we use to access the web on mobile phones.

Spreadex required to sell Sporting Index

25/11/2024 09:25:00

An independent CMA panel has decided Spreadex should sell Sporting Index after finding the deal harmed competition for licensed online sports spread betting services.